| Similar Articles |
|---|
 |
The Motley Fool
January 28, 2005
Brian Gorman |
Baxter Plods On 2005 looks like another year of transition for Baxter International. The medical products and services concern reported that after currency adjustments, fourth-quarter 2004 revenue of $2.6 billion was essentially flat compared with the same period in 2003.   |
The Motley Fool
December 23, 2003
Jeff Hwang |
Bad, Bad Baxter The medical products company issues its latest in a series of earnings warnings. |
The Motley Fool
January 23, 2009
Robert Steyer |
BAX to the Future After minding its own business, Baxter International starts thinking about acquisitions again. |
The Motley Fool
April 22, 2005
Brian Gorman |
Baxter Is on the Mend The medical products company continues to right itself for a brighter future. The firm's long-term positioning and diversified business may make it worth a closer look. |
The Motley Fool
September 27, 2007
Billy Fisher |
Baxter Looking to Bounce Back Shares of the medical device maker finally rebound following a company recall of infusion pumps. |
The Motley Fool
October 19, 2007
Brian Orelli |
Baxter Gets Pumped Up Medical-device maker Baxter puts in a nice quarter despite two recent FDA recalls. |
The Motley Fool
April 17, 2009
Robert Steyer |
The Steady BAX Beat Baxter International's diverse medical offerings continue to produce prosperity. |
Chemistry World
December 6, 2012
Andrew Turley |
Baxter to pay $4bn for dialysis firm US drug maker Baxter has struck a deal to buy privately-owned Swedish firm Gambro, which makes dialysis products, for $4 billion |
Fast Company
April 2004
Keith H. Hammonds |
Moment of Truth? It has been a tortuous year for Harry M. Jansen Kraemer Jr., CEO of Baxter International Inc. Back in November 2002, we lauded Kraemer's forthright leadership as his company confronted the deaths of 53 patients due to contaminated dialysis filters made by a Baxter subsidiary. Now Kraemer is out of a job. |
The Motley Fool
January 25, 2008
Brian Orelli |
Where the Big Margins Are Drug company investors get to enjoy such high gross margins, but there's generally only so much improvement that a company can make when it starts from such a high point. Take a look at some pharma companies that are succeeding to do just that. |
The Motley Fool
August 26, 2008
Brian Orelli |
Baxter Ready to Sop Up Additional Revenue The health-care giant licenses a surgical sponge in clinical development. |
The Motley Fool
November 3, 2011
Dan Caplinger |
Has Baxter International Become the Perfect Stock? Baxter needs to keep working on getting its debt levels down and seek out new growth opportunities. With favorable demographic winds at its back, Baxter could be the rare stock to actually reach perfection. |
The Motley Fool
July 20, 2007
Brian Orelli |
Baxter's Mixed Message A recall of Baxter BioScience's COLLEAGUE infusion pumps seems to have over-shadowed healthy quarterly earnings reports. |
The Motley Fool
March 7, 2008
Brian Lawler |
A Little Too Much Drug Variability Another drugmaker has to recall batches of its compound. |
The Motley Fool
May 29, 2008
Brian Lawler |
Human Genome's Jam-Packed Pipeline This drugmaker has plentiful candidates heading for phase 3 testing. |
The Motley Fool
April 18, 2008
Brian Orelli |
Recalls Can't Beat Baxter In spite of charges for two recalls, Baxter posts a decent quarter. |
The Motley Fool
September 24, 2008
Brian Orelli |
Hey, You! Stop! The FDA has ordered Baxter and Hospira to stop making their ophthalmic balanced salt solutions within 60 days. |
The Motley Fool
October 20, 2005
Stephen D. Simpson |
Baxter Needs Growth Infusion This is a fine health-care company, but a sluggish top line suggests there are limits to how far it can go. Trading at nearly 20 times forward earnings, it seems like expectations of a growth revival are already in the stock. |
The Motley Fool
April 20, 2006
Stephen D. Simpson |
Baxter Bags Better Margins This is a great business -- but only at the right price. Investors, this story has to be bought cheap. At today's prices, is it cheap enough? |
The Motley Fool
August 30, 2007
Brian Orelli |
Forget What Your Drug Was Approved For Baxter stages a new trial for an old drug. |
Fast Company
November 2002
Keith H. Hammonds |
Harry Kraemer's Moment of Truth In an era when the business section read like the police blotter, the CEO of medical products and pharmaceutical company Baxter International faced a tough ethical dilemma. And he did something noteworthy: He actually did the right thing. |
Registered Rep.
June 14, 2007
Kevin Burke |
Pilgrim Baxter's Payback The SEC announced this week that it is returning ill-gotten gains to Pilgrim Baxter (investment advisor to the PBHG fund family) shareholders, three and half years after the fund company was engulfed in a trading scandal. |
The Motley Fool
October 16, 2009
Robert Steyer |
Baxter Beats Again -- the Streak Is Alive! The drug, device, and medical services giant beats Wall Street earnings estimates by a penny, but flat sales signal caution. |
The Motley Fool
February 29, 2008
Brian Orelli |
Bigger Recall, No Big Deal Baxter increases its recall of heparin, but investors shouldn't be that worried. |
The Motley Fool
April 10, 2008
Brian Orelli |
The News for Baxter Just Got Worse These heparin-related deaths aren't associated with Baxter's product, but they still might spell trouble for the company. |
IndustryWeek
January 1, 2009
David Drickhamer |
Baxter Mexico: IW Best Plants Profile 2008 Lean Medical Marvel: Baxter Mexico transforms its production processes from the bottom up. |
